New drug combo shows promise in early brain cancer trial
NCT ID NCT06095375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested adding the targeted drug regorafenib to standard chemotherapy (temozolomide) with or without radiation for people with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The study involved 21 participants and aimed to find the safest dose of regorafenib when used alongside standard treatments. The goal is to see if this combination can help control the disease better than current approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib (a targeted cancer drug) combined with temozolomide (chemotherapy)
- What this could lead to
- If successful, this could lead to a new treatment option that improves outcomes for patients with a hard-to-treat brain cancer.
- What could go wrong
- This is a very early phase 1 trial with only 21 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanitas Research Hospital
Rozzano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo targets Hard-to-Treat brain tumors
- Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?
- Lab test aims to match brain tumor patients with targeted drugs
- Brain cancer breakthrough? new trial delivers drug straight to tumor
- Glowing dye could help surgeons spot hidden brain cancer
- Ultrasound device opens brain barrier to attack deadly tumors